Egypt Oncology Clinical Trials Market Report 2022 to 2030

Egypt Oncology Clinical Trials Market Analysis

$ 3999

Egypt's oncology clinical trials market is projected to grow from $35.4 Mn in 2022 to $60.9 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by Egypt's rising cancer incidence and the government's favorable regulatory framework for clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer Inc., Novartis International, EIPICO & EVA Pharma

ID: IN10EGCT006 CATEGORY: Clinical Trials GEOGRAPHY: Egypt AUTHOR: Vidhi Upadhyay

Buy Now

Egypt Oncology Clinical Trials Market Executive Summary

Egypt's oncology clinical trials market is projected to grow from $35.4 Mn in 2022 to $60.9 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. Egypt is split into four major geographical regions: the Nile River and Delta, the Sinai Peninsula, the Eastern Desert, and the Western Desert. Egypt has the biggest number of clinical trials being conducted by pharmaceutical corporations such as Roche and Novartis in Africa, second only to South Africa. Egypt executes the most clinical trials in the Middle East when compared to other Arab nations, and combined with Saudi Arabia oversees half of all clinical research in the area. In Egypt in 2020, the following cancers had the largest incidence numbers: liver (27,895), breast (22,038), bladder (10,655), Non-Hodgkin Lymphoma (7305), lung (6538), leukaemia (5231), and prostate (4767), with a total of 134,632 for all cancers.

Egypt's oncology clinical trials landscape is promising, with an increasing number of clinical studies being done across a variety of diseases and treatment interventions such as breast cancer, lung cancer, colorectal cancer, lymphoma, pediatric cancers. To advance the area of oncology clinical trials in Egypt, further investment in healthcare facilities, research skills, and patient education is required. The landscape for oncology clinical trials in Egypt is expanding and diversifying, with increased interest and investment from both local and international actors.

egypt oncology clinical trials market analysis

Market Dynamics

Market Growth Drivers

One of the primary growth factors is Egypt's rising cancer incidence, which is fuelling demand for innovative and better therapies. Another motivator is the Egyptian government's favorable regulatory framework for clinical research, which has been designed to facilitate clinical trials. The Egyptian Drug Authority and the Ministry of Health have set criteria for clinical studies, and the clearance procedure has grown more simplified in recent years. Moreover, international cooperation has aided in the promotion and support of oncology clinical trials in Egypt. Foreign institutions such as the National Cancer Institute (NCI) and the World Health Organization (WHO) have been collaborating with Egyptian researchers and healthcare professionals to increase the number of oncology clinical trials in the country.

Market Restraints

There are other constraints to consider as well. One of the most significant issues is the scarcity of research funding, which may obstruct the development of novel medicines and the conduct of clinical studies. Another issue is that patients and healthcare professionals are not aware of the relevance and advantages of clinical trials. This may result in poor enrolment rates and delayed recruiting, extending the time required to complete studies. Another constraint is the country's insufficient research infrastructure in some areas. Consequently, Egypt's political and economic instability may have an influence on the expansion of oncology clinical trials, especially if it results in a decrease in financing or research activities.

Competitive Landscape

Key Players

Pfizer Inc.
Novartis International AG
AstraZeneca plc
Merck & Co., Inc.
Roche Holding AG
Eli Lilly and Company
Sanofi S.A.
Bristol Myers Squibb Company
Pharco Pharmaceuticals (EGY)
EIPICO (EGY)
EVA Pharma (EGY)

Notable Insights

September 2021, GE Healthcare, Gustave Roussy, and Egypt's Ministry of Health Join Together to Establish Rapid Breast Cancer Diagnosis Centers

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation

6. Methodology and Scope

Oncology Clinical Trials Market Segmentation

By Phase (Revenue, USD Billion):

Phase I
Phase II
Phase III
Phase IV

By Study Design Outlook (Revenue, USD Billion):

Epilepsy
Parkinson's Disease (PD)
Huntington's Disease
Stroke
Traumatic Brain Injury (TBI)
Amyotrophic Lateral Sclerosis (ALS)
Muscle regeneration
Others

By Indication Outlook (Revenue, USD Billion):

Interventional
Observational
Expanded Access

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.